格列齐特在糖尿病肾病治疗中带来肾获益的研究进展

发布时间：2018-10-20 14:35

【摘要】：目的:探讨口服降糖药物格列齐特在糖尿病肾病治疗中带来的肾获益。方法:查阅近年来国内外相关文献,就格列齐特在糖尿病肾病治疗中带来的肾获益进行归纳和总结。结果与结论:糖尿病肾病的发生与发展和高血糖、氧化应激和内皮功能障碍等密切相关。格列齐特为传统降糖药物,相关循证研究显示,该药可为糖尿病肾病患者带来肾获益,原因为其具有显著的降糖作用,以及其化学结构中独特的氮杂环结构。其中,该氮杂环结构能够接受活性自由基活性氧簇的电子,并发生构象变化,使自由基形成稳定结构,从而清除自由基,起到抗氧化应激、改善内皮功能的作用,是格列齐特带来肾获益效果的关键原因。同时,格列齐特能够显著降低糖尿病肾病患者发生微量白蛋白尿的风险,带来肾获益,但其具体机制还有待进一步研究验证。
[Abstract]:Objective: to investigate the renal benefits of oral glycosylated gliclazide in the treatment of diabetic nephropathy. Methods: to summarize the renal benefits of gliclazide in the treatment of diabetic nephropathy. Results & conclusion: the occurrence and development of diabetic nephropathy were closely related to hyperglycemia, oxidative stress and endothelial dysfunction. Gliclazide is a traditional hypoglycemic drug. Evidence-based studies have shown that it can benefit the kidney of patients with diabetic nephropathy because of its significant hypoglycemic effect and the unique nitrogen heterocyclic structure in its chemical structure. The nitrogen heterocyclic structure can accept the electrons of active oxygen species, and change the conformation of the free radicals, which makes the free radicals form a stable structure, thus scavenging the free radicals, playing the role of antioxidant stress and improving the endothelial function. It is the key reason why Gliclazide can benefit the kidney. At the same time, gliclazide can significantly reduce the risk of microalbuminuria in patients with diabetic nephropathy and benefit the kidney, but its mechanism needs further study.
【作者单位】：上海交通大学医学院附属新华医院药剂科;
【分类号】：R587.2;R692.9

【相似文献】